Search Results - "Small, E. J."

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 by Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D., Small, E. J.

“…Background: This phase II trial (Cancer and Leukemia Group B 90102) sought to determine the efficacy of cisplatin, standard infusion of gemcitabine and…”
Get full text

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm by Small, E J, Vogelzang, N J

“…To discuss the evolution of new concepts in the Use of second-line hormonal therapy for patients with progressive prostate cancer despite androgen deprivation…”
Get more information

CT Cervical Spine Fracture Detection Using a Convolutional Neural Network by Small, J.E., Osler, P., Paul, A.B., Kunst, M.

“…BACKGROUND AND PURPOSEMultidetector CT has emerged as the standard of care imaging technique to evaluate cervical spine trauma. Our aim was to evaluate the…”
Get full text

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group by BUBLEY, G. J, CARDUCCI, M, HUSSAIN, M, KAPLAN, R, MYERS, C, OH, W, PETRYLAK, D. P, REED, E, ROTH, B, SARTOR, O, SCHER, H, SIMONS, J, DAHUT, W, SINIBALDI, V, SMALL, E. J, SMITH, M. R, TRUMP, D. L, VOLLMER, R, WILDING, G, DAWSON, N, DALIANI, D, EISENBERGER, M, FIGG, W. D, FREIDLIN, B, HALABI, S, HUDES, G

“…Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic…”
Get full text

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 by Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.

“…Background: There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are…”
Get full text

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780 by SAVARESE, D. M, HALABI, S, HARS, V, AKERLEY, W. L, TAPLIN, M-E, GODLEY, P. A, HUSSAIN, A, SMALL, E. J, VOGELZANG, N. J

“…PURPOSE: To investigate the combination of docetaxel, estramustine (EM), and low-dose hydrocortisone in men with hormone-refractory prostate cancer (HRPC)…”
Get full text

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist by TAPLIN, M.-E, BUBLEY, G. J, KO, Y.-J, SMALL, E. J, UPTON, M, RAJESHKUMAR, B, BALK, S. P

“…The role of androgen receptor (AR) mutations in androgen-independent prostate cancer (PCa) was determined by examining AR transcripts and genes from a large…”
Get full text

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial by Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., del Corral, A., Francis, P., Kim, W., Efstathiou, E.

“…Patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous…”
Get full text

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer by Small, E.J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., Olmos, D., Mainwaring, P.N., Lee, J.Y., Uemura, H., De Porre, P., Smith, A.A., Zhang, K., Lopez-Gitlitz, A., Smith, M.R.

“…In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS)…”
Get full text

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal by Small, E J, Baron, A D, Fippin, L, Apodaca, D

“…We tested the hypothesis that certain patients with hormone refractory prostate cancer retain hormonal sensitivity even after progression following…”
Get more information

The Dominant Anterior Thoracic Artery of the Spinal Cord by Small, J E, Pérez Pérez, V H

“…Dominant radiculomedullary arteries such as the artery of lumbar enlargement and the artery of cervical enlargement are well-documented. However, variability…”
Get full text

CTA Evaluation of Basilar Septations: An Entity Better Characterized as Aberrant Basilar Fenestrations by Small, J E, Macey, M B, Wakhloo, A K, Sehgal, S

“…A basilar artery intraluminal septation is an exceedingly rarely reported, presumed congenital abnormality. In our clinical practice, we have occasionally…”
Get full text

Anatomy of the Great Posterior Radiculomedullary Artery by Perez Perez, V H, Hernesniemi, J, Small, J E

“…Although considerable variability exists as to the overall caliber of radiculomedullary arteries, dominant radiculomedullary arteries such as the artery of…”
Get full text

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry by Kwon, D.H., Vashisht, R., Borno, H.T., Aggarwal, R.R., Small, E.J., Butte, A.J., Huang, F.W.

Get full text

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer by KELLY, William Kevin, CURLEY, Tracy, GEORGE, Daniel, OH, William, SMITH, Matthew, KAUFMAN, Donald, SMALL, Eric J, SCHWARTZ, Lawrence, LARSON, Steve, TONG, William, SCHER, Howard, SLOVIN, Susan, HELLER, Glenn, MCCAFFREY, John, BAJORIN, Dean, CIOLINO, Allison, REGAN, Kevin, SCHWARTZ, Morton, KANTOFF, Philip

“…To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer. In…”
Get full text

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping by CHER, M. L, BOVA, G. S, MOORE, D. H, SMALL, E. J, CARROLL, P. R, PIN, S. S, EPSTEIN, J. I, ISAACS, W. B, JENSEN, R. H

“…A newly developed method of comparative genomic hybridization (CGH) employing quantitative statistical comparisons was applied to DNA from two different types…”
Get full text

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone by SMALL, E. J, MEYER, M, MARSHALL, M. E, REYNO, L. M, MEYERS, F. J, NATALE, R. B, LENEHAN, P. F, LIANG CHEN, SLICHENMYER, W. J, EISENBERGER, M

“…Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective…”
Get full text

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer by Halabi, S, Dutta, S, Tangen, C M, Rosenthal, M, Petrylak, D P, Thompson, Jr, I M, Chi, K N, De Bono, J S, Araujo, J C, Logothetis, C, Eisenberger, M A, Quinn, D I, Fizazi, K, Morris, M J, Higano, C S, Tannock, I F, Small, E J, Kelly, W K

“…We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate…”
Get full text

Therapy of Advanced Prostate Cancer with Granulocyte Macrophage Colony-stimulating Factor by SMALL, E. J, REESE, D. M, UM, B, WHISENANT, S, DIXON, S. C, FIGG, W. D

“…Granulocyte macrophage colony-stimulating factor is a pleiotropic cytokine capable of inducing systemic immune responses against experimental and human tumors…”
Get full text

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 by Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

“…The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most…”
Get full text